Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Popovici, Vlad ^a,b   Budinska, Eva ^a,b   Bosman, Fred T ^c   Tejpar, Sabine ^d   Roth, Arnaud D ^e   Delorenzi, Mauro ^b,f  

^a MASARYK UNIVERSITY   (Czech Republic)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

BRAF V600E mutation; Colorectal cancer; KRAS mutations; Stratified analysis; Survival analysis

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; GENE MUTATION; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PATIENT CODING; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR LOCALIZATION;

COLORECTAL NEOPLASMS; HUMANS; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84884666514     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-439     Document Type: Article

References (22)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532. 10.1056/NEJM198809013190901, 2841597.
2. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. Allelotype of colorectal carcinomas. Science 1989, 244:207-211. 10.1126/science.2565047, 2565047.
3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009, 361:2449-2460. 10.1056/NEJMra0804588, 2843693, 20018966.
4. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006, 25:7531-7537. 10.1038/sj.onc.1210059, 17143297.
5. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005, 65:6063-6069. 10.1158/0008-5472.CAN-05-0404, 16024606.
6. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008, 3:e3698. 10.1371/journal.pone.0003698, 2579485, 19002263.
7. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruine AP, Goldbohm RA, van den Brandt PA. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003, 24:703-710. 10.1093/carcin/bgg009, 12727799.
8. English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, Walsh MD, Buchanan DD, Barker MA, Haydon AM, Royce SG, Roberts A, Parry S, Hopper JL, Jass JJ, Giles GG. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2008, 17:1774-1780. 10.1158/1055-9965.EPI-08-0091, 18628431.
9. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VEPP, Rutten HJT, van den Brule AJC. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010, 21:2396-2402. 10.1093/annonc/mdq258, 20501503.
10. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL. Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. Clin Cancer Res 2012, 18:6531-6541. 10.1158/1078-0432.CCR-12-0605, 23045248.
11. Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, Oki E, Ohga T, Kitao H, Kakeji Y, Maehara Y. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. Int J Clin Oncol 2012, 1-7. http://dx.doi.org/10.1007/s10147-012-0501-x.
12. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012, 18:890-900. 10.1158/1078-0432.CCR-11-2246, 3271172, 22147942.
13. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474. 10.1200/JCO.2009.23.3452, 20008640.
14. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012, 36:744-752. 10.1097/PAS.0b013e31824430d7, 22314188.
15. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011, 29:1261-1270. 10.1200/JCO.2010.30.1366, 21383284.
16. Ren J, Li G, Ge J, Li X, Zhao Y. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum 2012, 55:913-923. 10.1097/DCR.0b013e318251d8d9, 22810479.
17. Tejpar S, Bertagnolli MM, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010, 15:390-404. 10.1634/theoncologist.2009-0233, 3227961, 20350999.
18. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, Andre T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125. 10.1200/JCO.2008.21.6663, 19451425.
19. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, Nordlinger B, Bosman F, Van Cutsem E. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012, 104:1635-1646. 10.1093/jnci/djs427, 23104212.
20. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012, 30:3570-3577. 10.1200/JCO.2012.42.2592, 22734028.
21. Tejpar S, Popovici V, Delorenzi M, Budinska E, Estrella H, Mao M, Yan P, Weinrich S, Van Cutsem E, Roth A. Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2010, 28(suppl):262s. abstr 3505. ASCO Annual Meeting abstract 3505.
22. Popovici V, Budinska E, Tejpar S, D'Ario G, Di Narzo AF, Hodgson JG, Roth A, Bosman F, Delorenzi M. Molecular and clinicopathologic evidence of heterogeneity in KRAS-mutant colon cancers. J Clin Oncol 2012, 30(15_suppl):abstr 3575. ASCO Annual Meeting abstract 3575.